The influence of endocrine treatments for breast cancer on health-related quality of life

Autor: Marian J.E. Mourits, Elisabeth G.E. de Vries, Ciska Buijs, Pax H.B. Willemse
Jazyk: angličtina
Rok vydání: 2008
Předmět:
Oncology
Health-related quality of life
MEGESTROL-ACETATE
law.invention
DOUBLE-BLIND
Breast cancer
Randomized controlled trial
Quality of life
law
COMBINATION TRIAL
Aromatase
Fulvestrant
Premature Menopause
Mastectomy
Randomized Controlled Trials as Topic
biology
Estradiol
Aromatase Inhibitors
General Medicine
Middle Aged
Prognosis
Postmenopause
Treatment Outcome
POSTMENOPAUSAL WOMEN
Chemotherapy
Adjuvant
Female
medicine.drug
Adult
medicine.medical_specialty
Neoplasms
Hormone-Dependent
Antineoplastic Agents
Hormonal
Breast Neoplasms
Risk Assessment
Drug Administration Schedule
SELECTIVE AROMATASE INHIBITOR
Internal medicine
medicine
Endocrine system
Humans
INTERGROUP EXEMESTANE
Radiology
Nuclear Medicine and imaging
CONTINUED TAMOXIFEN
SURGICAL ADJUVANT BREAST
Aged
Gynecology
Dose-Response Relationship
Drug
business.industry
medicine.disease
Survival Analysis
RANDOMIZED-TRIAL
Tamoxifen
Premenopause
ONCOLOGY-TECHNOLOGY-ASSESSMENT
biology.protein
Quality of Life
business
Hormonal therapies
Zdroj: CANCER TREATMENT REVIEWS. 34(7):640-655
ISSN: 0305-7372
DOI: 10.1016/j.ctrv.2008.04.001
Popis: Many hormonal modalities are available for breast cancer treatment, such as selective oestrogen receptor modulators (SERMs), aromatase inhibitors, progestins and luteinising hormone-releasing hormone (LHRH) agonists. The Long-term impact of these endocrine manipulations is an issue, because the duration of adjuvant treatment is still increasing, as is the number of breast cancer survivors. Premature menopause is induced at a young age, and may often be permanent after chemotherapy. The purpose of this review is to provide a literature-based overview of the side effects of endocrine treatment in pre- and postmenopausal breast cancer patients and the influence on HRQoL, especially on sexual functioning. The collection of health-related quality of life (HRQoL) data can result in better treatment recommendations during endocrine therapy. Methods: This review was Limited to prospective randomised studies in English Literature from between 1977 and 2007 and provides an overview of the effects on HRQoL and sexuality of various hormonal treatment in pre- and postmenopausal breast cancer patients, both in the adjuvant and palliative setting. Relevant clinical studies were identified by using the Medline database. Results: HRQoL mostly is severely influenced by chemotherapy and part of these symptoms may be tasting, especially when associated with the induction of premature menopause. Similar symptoms may be encountered during ovarian suppression therapy by LHRH analogs, but they will. usually prove to be reversible. The varying side effect profiles of tamoxifen and aromatase inhibitors did not lead to significant difference in overall HRQoL. HRQoL during progestins and the SERM fulvestrant has been compared to this during aromatase inhibitors, and a large number of studies on HRQoL during endocrine therapy wilt be discussed. (C) 2008 Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: